Lilly CEO: Pharma will snub Boston

Eli Lilly CEO John Lechleiter isn't happy with new Massachusetts legislation governing the way drugmakers market their products to doctors: He's saying that the limits will hamper innovation and force companies to reconsider expanding in the state. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.